在初级艾滋病毒期间启动的三个月的cART没有纠正胃肠道内的结构,免疫和微生物异常
Camilla Tincati1, Valeria Bono1, Silvia Nozza2
1Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Italy.
Pathogens & immunity
|November 21, 2025
概括
针对原发性艾滋病毒感染 (PHI) 的早期组合抗逆转录病毒疗法 (cART) 并没有逆转与艾滋病毒相关的肠道损伤或炎症. 这表明早期cART在解决驱动并发症的促炎特征方面的有效性有限.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 微生物组研究 微生物组研究
背景情况:
- 艾滋病毒感染严重影响肠道结构,免疫力和微生物群,导致免疫活性和炎症.
- 这些肠道变化有助于艾滋病毒感染者 (PLWH) 的非传染性并发症.
- 在原发性艾滋病毒感染 (PHI) 期间开始的组合抗逆转录病毒疗法 (cART) 对胃肠道健康的疗效在很大程度上是未知的.
研究的目的:
- 为了研究12周cART对胃肠道结构,免疫力和粘膜微生物群在PHI的PLWH的影响.
- 评估早期的病毒抑制治疗是否可以逆转与艾滋病毒相关的肠道异常.
主要方法:
- 11名患有PHI的参与者接受了结肠镜检查,包括活检,外周血液单核细胞 (PBMC),以及在cART治疗12周前后收集血.
- 肠道活检分析了结构变化 (E-cadherin,原) 和免疫细胞群 (巨细胞,T细胞).
- 分析了PBMC和肠道组织微生物组组成.
主要成果:
- 尽管12周的cART,肠道屏障损伤 (E-cadherin损失,原沉积) 在PHI参与者中进展.
- CD4+和γδT细胞频率保持稳定,结肠激活减少,但Th17和Treg细胞没有变化.
- 周围炎症和肠道屏障完整性标志物没有显著变化;然而,肠道微生物组的组成演变.
结论:
- 早期启动12周的cART并不能纠正艾滋病毒媒介的肠道损伤或完全恢复促炎特征.
- 尽管早期治疗,但持续的肠道损伤表明cART在预防长期并发症方面的有效性有限.
- 这些发现突显了持续性肠道损伤和PLWH中非传染性并发症的发展之间的病原遗传联系.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Retrovirus Life Cycles
49.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
620
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
620
Drugs for Treatment of Diarrhea-Predominant IBS
604
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
604
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435


